|
|
Article: Phase III pivotal trial for STR begins.
- Article from:
- Immunotherapy Weekly
- Article date:
- April 28, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 APR 28 - (NewsRx.com & NewsRx.net) -- NeoRx Corp. (NERX) has opened the phase III clinical trial of its lead cancer therapeutic, STR (Skeletal Targeted Radiotherapy), to patient enrollment.
NeoRx is developing STR for use with high-dose chemotherapy and autologous (self-donor) stem cell transplantation to treat multiple myeloma and other cancers that arise in or spread to the bone and bone marrow.
"We are pleased to announce the opening of the first clinical sites on our phase III pivotal trial of STR," said Jack L. Bowman, chairman and CEO. "We plan to conduct this trial at up to 40 clinical sites in the U.S. and Canada, opening sites on a rolling ...